Loncom Pharma

Loncom Pharma, officially Beijing Loncom Pharmaceutical Co., Ltd., is a specialized Chinese pharmaceutical company primarily focused on women's health and dermatology. The company is best known for its "Langyi" brand, which maintains a leading position in the Chinese market for gynecological anti-infective treatments. Its flagship products include clotrimazole vaginal tablets and nifuratel-nystatin combinations used to treat various forms of vaginitis. In 2016, Loncom was acquired by China Resources Double-Crane Pharmaceutical, a subsidiary of the state-owned China Resources Pharmaceutical Group, for approximately 850 million RMB. The company operates advanced manufacturing facilities that adhere to national GMP standards and continues to expand its portfolio in the reproductive health sector. Loncom is recognized as a high-tech enterprise and remains a key business unit within the China Resources healthcare ecosystem.